Search
Curcumin
go.drugbank.com/drugs/DB11672ApprovedInvestigationalCurcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in Curcuma xanthorrhiza oil. It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglyce...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesFruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigationalFruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis. Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesPacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigational10<sup>9</sup>/L. … well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment of both primary and secondary MF in patients with platelet counts < 50 x
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersAcalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigationalTo date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administer...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsEncorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalEncorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesIcotinib
go.drugbank.com/drugs/DB11737InvestigationalIcotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersVonoprazan
go.drugbank.com/drugs/DB11739ApprovedInvestigationalVonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits H+, K+-ATPase-mediated gastric acid secretion. PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. Unlike proton-pu...
Synonyms: 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamineCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesEbastine
go.drugbank.com/drugs/DB11742ApprovedInvestigationalWithdrawnEbastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTalazoparib
go.drugbank.com/drugs/DB11760ApprovedInvestigationalTalazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib wa...
Categories: P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic IndexTenapanor
go.drugbank.com/drugs/DB11761ApprovedInvestigationalTenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C). It was first designed and synthesized in 2012. As an inhibitor of the sodium/hydro...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates